Articles

Shire to acquire NPS Pharma for $5.2 billion

Decision to buy the rare disease-focused biopharmaceutical company is a further step by Shire to build itself into a leading biotech
Written byJeffrey Bouley
| 4 min read

DUBLIN & BEDMINSTER, N.J.—Although AbbVie Inc. and Shire PLC were unable to come to a final merger deal in October 2014 after the U.S. Treasury instituted new rules to discourage inversion deals, the termination of the deal did leave Shire with a breakup fee of $1.6 billion. An amount of money which no doubt is helping Shire as it makes its first deal since the aborted AbbVie one—this time, looking to acquire NPS Pharmaceuticals Inc., a commercial-stage rare disease-focused biopharmaceutical company, for $5.2 billion.

Under the deal, Shire will acquire all the outstanding shares of NPS Pharma for $46 per share in cash—a 51-percent premium to NPS Pharma's unaffected share price on Dec. 16, 2014—with Shire intending to “accelerate the growth of NPS Pharma's innovative portfolio through its market expertise in gastrointestinal (GI) disorders, core capabilities in rare disease patient management, and global footprint.”

The transaction has been approved unanimously by the boards of directors of both Shire and NPS Pharma.

NPS Pharma’s first product, Gattex/Revestive (teduglutide [rDNA origin]) for injection, is approved in the United States and Europe to treat adults with short bowel syndrome (SBS) who are dependent on parenteral support. NPS Pharma also has a registration-phase product, Natpara/Natpar (rhPTH [1-84]) for the treatment of hypoparathyroidism (HPT).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.